大行评级｜高盛：下调默沙东目标价至94美元 次季盈利胜预期但财务和前景更新较为复杂

Group 1 - Goldman Sachs reported that Merck's Q2 earnings exceeded expectations, but the financial outlook is complex [1] - There is ongoing uncertainty regarding the exclusivity of Gardasil in China and the U.S., leading Goldman Sachs to lower its target price from $99 to $94 [1] - The positive news includes the strong performance of the company's main new product, Winrevair, with management maintaining an optimistic outlook [1] Group 2 - The Q2 revenue slightly missed expectations, and the company announced a new restructuring plan [2] - Merck's stock experienced a decline of approximately 8.8% following the news [2]